Verition Fund Management LLC Sells 186,297 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Verition Fund Management LLC reduced its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 84.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 33,530 shares of the biotechnology company’s stock after selling 186,297 shares during the quarter. Verition Fund Management LLC’s holdings in Aldeyra Therapeutics were worth $181,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. Captrust Financial Advisors boosted its stake in shares of Aldeyra Therapeutics by 89.3% during the 3rd quarter. Captrust Financial Advisors now owns 19,261 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 9,087 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Aldeyra Therapeutics by 253.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 14,229 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 10,201 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Aldeyra Therapeutics during the 3rd quarter worth approximately $79,000. King Wealth Management Group raised its position in shares of Aldeyra Therapeutics by 24.5% in the 3rd quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 2,700 shares in the last quarter. Finally, US Bancorp DE bought a new position in shares of Aldeyra Therapeutics in the 3rd quarter worth approximately $30,000. 59.71% of the stock is owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Price Performance

NASDAQ:ALDX opened at $5.06 on Tuesday. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. The firm’s 50-day moving average price is $5.15 and its 200-day moving average price is $4.74. Aldeyra Therapeutics, Inc has a 1-year low of $2.71 and a 1-year high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.25). On average, sell-side analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current year.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.